Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Matinas BioPharma MTNB is gonna be a rocket.
--Positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis.
--The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
--In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first ten weeks of antifungal treatment.
--Enrollment in Cohort 3 of EnACT has commenced and is expected to complete by the end of 2021. Cohort 3 is the safety lead-in for Cohort 4, an all-oral MAT2203 treatment regimen.
Matinas BioPharma MTNB is gonna be a rocket, with good news!
--Positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis.
--The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
--In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first ten weeks of antifungal treatment.
--Enrollment in Cohort 3 of EnACT has commenced and is expected to complete by the end of 2021. Cohort 3 is the safety lead-in for Cohort 4, an all-oral MAT2203 treatment regimen.
I hold MTNB tightly till $3.00-- soon this year!
---------------
The 5 analysts offering 12-month price forecasts for Matinas BioPharma Holdings Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 0.90. The median estimate represents a +169.06% increase from the last price of $1.12. The current consensus among 5 polled investment analysts is to BUY stock in Matinas BioPharma Holdings Inc. This rating has held steady since August 2021, when it was unchanged from a BUY rating.
https://money.cnn.com/quote/forecast/forecast.html?symb=MTNB
$60M Cash & No Debt (~$5M Qtrly Burn)
Great read.Thanks blh28
This is a great read, with potential valuation...
https://www.griproom.com/fun/matinas-is-go-flight-for-rocket-launch
Maybe an offering coming low on cash ?
Like the last line in this report.
https://stocksregister.com/2021/09/14/matinas-biopharma-holdings-inc-amex-mtnbs-stock-adds-27-12-but-it-may-be-worth-investing-in/
Words going to be getting out to the world.
Matinas BioPharma Stock Jumps After Meningitis Candidate Data
Vandana Singh , Benzinga Staff Writer FOLLOW
September 13, 2021 8:36am 1 min read Comments
Thousands of traders are getting a 90% win-rate trading options! Click Here to See How!
Matinas BioPharma Stock Jumps After Meningitis Candidate Data
Matinas BioPharma Holdings Inc MTNB +undefined% (Get Free Alerts for MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis.
The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
In the second cohort, step-down therapy with MAT2203 achieved an effective clearance of fungal organisms was 0.38, significantly higher than the prespecified primary endpoint threshold of over 0.20. Cohort 2 evaluated stepdown to MAT2203 after two days of IV amphotericin.
There was no evidence of breakthrough or relapsed cryptococcal infections through 10 weeks. In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.
All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first ten weeks of antifungal treatment.
Enrollment in Cohort 3 of EnACT has commenced and is expected to complete by the end of 2021. Cohort 3 is the safety lead-in for Cohort 4, an all-oral MAT2203 treatment regimen.
Price Action: MTNB shares are up 8.96% at $0.90 during the premarket session on the last check Monday.
Yeap, great news coming for MTNB!
Hold tight for $2 this year, definitely
Very conservative with just a tad more good news.AIMHO...
What a day here.. great news more coming
I expect estimates to be adjusted higher after today's news.
Target is $2.48. Based on 4 Wall Street analysts offering 12 month price targets for MTNB--Matinas BioPharma in the last 3 months. The average price target is $2.48 with a high forecast of $3.00 and a low forecast of $0.90. The average price target represents a 133.96% change from the last price of $1.06.
Great points Lawman.This is about to get very interesting.
The results announced today, for the LNC version of amphotericin b, are for a trial sponsored and funded by the NIH.
Dr. Fauci also asked MTNB to use its LNC platform to try and make an oral version of Remdesivir that is safe and effective.
That study is also being funded by the NIH.
So, it appears the NIH is very supportive of MTNB, and its LNC platform, which makes FDA approval of various LNC formulations, including MAT 2202 and MAT 2501, highly probable in my opinion.
The Remdesivir results, along with the results of numerous collaborations with a who's who list of big pharmaceutical companies, could be announced at any time.
I have to believe that at some point one of MTNB's big pharma collaborators is going to make an offer to buy the company.
Whether that offer is made before the FDA approves one or more of MTNB's encochleated drugs, and whether the purchase includes Lypsido, are the only questions in my mind.
It would be imprudent, in my opinion, to sell any shares in MTNB at this time.
Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
September 13 2021 - 06:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced positive efficacy and safety data from the first two cohorts of patients in the ongoing Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) of MAT2203 (oral amphotericin B) for the treatment of cryptococcal meningitis, which is being sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
The EnACT independent Data and Safety Monitoring Board (DSMB) recently completed a pre-specified review of available safety and efficacy data from Cohort 2 (stepdown to MAT2203 after two days of IV amphotericin) and unanimously recommended progression to the second half of the study. Enrollment in Cohort 3 of EnACT (the safety lead-in for Cohort 4, which will be an all-oral MAT2203 treatment regimen) has commenced and is expected to complete by the end of 2021.
“These results are a major milestone for Matinas, MAT2203 and our LNC platform delivery technology,” stated Jerome D. Jabbour, Chief Executive Officer of Matinas. “These data are a clear demonstration of how our LNC platform can have a meaningful clinical impact in a deadly disease, and a validation of how this technology can be used to overcome significant drug delivery challenges, including oral delivery of highly toxic drugs across the blood-brain barrier. The global invasive fungal infection market is projected to be more than $8 billion by 2025, and we believe an oral and well tolerated amphotericin B, which preserves the well-established efficacy of this potent drug, if approved, could be poised to capture a meaningful portion of this growing market, and fill a currently large unmet medical need. Finally, we believe these data are supportive of the enormous potential for our LNC platform delivery technology and a key for potential partners and collaborators who are currently evaluating MAT2203 and broader applications of the LNC platform to antivirals, vaccines, and nucleic acid polymers, such as mRNA.”
Would be nice to know if you now had 1.2 bil. extra dollars perhaps to use on other things....
Good news for Gilead today.
https://news.yahoo.com/gilead-sciences-wins-reversal-1-154757831.html
That post was meant for my Aunt G.
Gilead and Matinas May Have Beaten Covid-19
https://www.griproom.com/fun/gilead-and-matinas-may-have-beaten-covid-19
Oral Remdesivir
DEC 2020 RELEASE:
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
https://www.globenewswire.com/news-release/2020/12/07/2140383/0/en/Matinas-BioPharma-Announces-Collaboration-with-the-National-Institute-of-Allergy-and-Infectious-Diseases-to-Evaluate-Oral-Formulations-of-Gilead-s-Antiviral-Remdesivir-Utilizing-Ma.html
Aug 10th (Q2 call)
"Today, we are extremely pleased to report that the Company and the National Institute of Allergy and Infectious Disease within NIH have successfully completed the planned in vitro studies of various LNC formulations of Remdesivir. LNC Remdesivir formulations were tested for anti-viral activity against the Washington SARS-CoV-2 strain in [Indiscernible] which are highly permissive for SARS-CoV-2 infections.
Unformulated Remdesivir active was tested as a comparison. Following close review of these data with NIAID the LNC formulations tested in this model demonstrated meaningful antiviral activity as compared to free Remdesivir, while also showing a favorable toxicity profile.
Given the impressive nature of these data NIAID is now preparing to initiate an in vivo efficacy study of the most potent LNC Remdesivir formulation as soon as possible. We expect additional data to be available in the fourth quarter of 2021.
These in-vitro data represent a big step forward, in not only showing that our LNC Platform can be potentially effectively used to create an oral formulation of Remdesivir, but are also an important proof of principle for the intracellular delivery of antiviral medicines more broadly. As we face the ongoing reality of a continued fight against COVID-19, the need for effective, well-tolerated antiviral drugs that can be given to patients at high risk for severe disease at early stages of illness remains extremely high.
An oral version of Gilead's remdesivir has the potential to be an important option for physicians around the world in the fight against COVID-19, since an oral remdesivir would permit administration earlier in the disease course, as well as potential for prophylactic use, should clinical studies support such an approach.
We are very happy with our progress to date on this project and look forward to -- with great anticipation to the NIH's planned in vivo study in the near-term."
On the brink of some very good news on several fronts,pluss there is always the chance of BLOW OUT NEWS,like a buy out.
Holding,and buying when i can.
LYPDISO™ (MAT9001)
Set to become the most effective omega-3 therapy.
Leveraging nearly 40 years of research in omega-3 therapy, we have developed LYPDISO – a proprietary prescription drug. It is comprised of a unique mix of potent omega-3 free fatty acids, most notably eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA). Throughout our development program, LYPDISO has demonstrated, among other benefits, absorption and triglyceride-lowering abilities that exceed those of existing omega-3 therapies.
It is the only omega-3 pharmaceutical product specifically designed to treat dyslipidemia – conditions related to elevated lipids in the blood (cholesterol and triglycerides). The initial targeted indication for LYPDISO is in patients with triglycerides over 500mg/dl.
As elevated triglycerides, especially very high levels, can lead to deadly cardiac events like heart attacks and strokes, LYPDISO is positioned to become a foundational tool for improving heart health.
A clear difference.
LYPDISO incorporates highly differentiating mechanistic features, intended to overcome shortcomings of existing therapies in the omega-3 class.
Unique Formulation
UNIQUE FORMULATION
High Potency
HIGH POTENCY
Specially Engineered
SPECIALLY ENGINEERED
Enhanced Absorption
ENHANCED ABSORPTION
Recognizing the dangers of triglycerides.
Elevated triglycerides have been strongly linked to cardiovascular risk in multiple longitudinal studies. However, the notion that lowering triglycerides can potentially be a significant factor in reducing risk has only been acknowledged by the scientific community in the last decade or so.
Omega-3 fatty acids are a foundational part of the treatment of elevated triglycerides. As new studies emerge, it’s becoming increasingly clear that prescription omega-3s (unlike lower-dose, less pure supplements) are associated with meaningful clinical benefits. The higher the dose, the greater the potential benefit. High-dose omega-3s may also have beneficial effects beyond triglyceride reduction
Based on promising early data, Matinas filed an Investigational New Drug Application (IND) with the FDA in 2014.
The path to clinical success.
LYPDISO is currently in Phase 2 clinical development, but we have already completed one important study with compelling results, showing the drug to have greater bioavailability and potency than Vascepa®, one of the leading prescription omega-3 agents. We intend to further test and develop LYPDISO in a series of upcoming trials.
LYPDISO
Hypertriglyceridemia
Pipeline
COMPLETED STUDIES
Head-to-Head Study of LYPDISO (4g) vs. Vascepa® (4g)
OBJECTIVE
A randomized, open-label, active-controlled, pharmacokinetic (PK)/pharmacodynamic (PD) trial of LYPDISO against marketing leading drug, Vascepa® (icosapent ethyl).
OVERVIEW
Study Population: 42 patients
Inclusion Criteria: Patients with triglyceride levels between 200-400 mg/dL (without lipid-altering Rx) and between 200-350 mg/dL (with stable–dose statin monoRx); men and women,18-70 years of age.
Trial Design: Patients were given a daily 4g dose of one drug 30 minutes after a meal. This occurred for the course of 14 days, with drug levels measured at days 1 and 14. Triglycerides and other blood lipid protein levels were measured throughout. After a 5-week washout period, patients returned to baseline and received the same treatment with the other drug for another 14 days.
RESULTS
LYPDISO demonstrated superiority in lowering TGs, total- and non-HDL-cholesterol, VLDL cholesterol, apolipoproteins CIII and PCSK9 levels. It achieved a 33% reduction in triglycerides from the baseline, compared to Vascepa® at 10.5%. In these patients on a low-fat diet, LYPDISO was found to be six times more bioavailable than Vascepa®.
Median Changes
Median Changes Two
Development Plan
Registration Studies
PK Bridging Study with Lovaza®:
As part of our regulatory program, in 2020, we have conducted a comparative crossover study to assess the bioavailability of LYPDISO and Lovaza® in 36 healthy volunteers. Patients were randomized to receive a single daily 4g dose of a study drug, have blood levels measured, undergo a 14-day wash-out period to return to baseline, be treated with a single dose of the other drug, and have final blood samples drawn.
Phase 3:
Pending discussions with the FDA, we plan to conduct at least one placebo controlled Phase 3 clinical study. The initial Phase 3 trial will assess the efficacy of LYPDISO in patients with severe hypertriglyceridemia (TGs > 500 mg/dL). Approximately 390 patients will be treated over the course of 12 weeks.
Differentiation Studies
ENHANCE-IT:
In 2020, LYPDISO will also be evaluated in a second, confirmatory head-to-head pharmacodynamic trial versus Vascepa®. This crossover trial is similar to the previous study, but will involve 100 patients with elevated TGs (150-499 mg/dL), on a standard TLC diet, randomized and treated for 28 days with study drug, washed out for 28 days, and then treated for another 28 days with the other drug. The primary endpoint will be the percent of TG reduction compared to baseline for that treatment period, and additional blood levels of Omega-3s will be obtained. We expect this study will confirm the previously observed superiority of LYPDISO.
Matinas BioPharma Holdings, Inc.
SCIENCE
LNC PLATFORM
MAT2203
MAT2501
LYPDISO™ (MAT9001)
INVESTORS
COMPANY PROFILE
STOCK DATA
ANALYST COVERAGE
GOVERNANCE
PRESS RELEASES
EVENTS
PRESENTATIONS
SEC FILINGS
COMPANY
OVERVIEW
OUR TEAM
NEWS
CAREERS
CONTACT US
REGISTER FOR UPDATES
Email
Email Address
Director of Drug Product Development
Director of Drug Product Development to lead drug product development with a focus on lipid based formulations. The individual will play an essential role in cross-functional teams and will be responsible for driving activities related to drug product process & manufacturing development. The primary responsibility will be for a mid/late-stage product development and NDA preparation. The responsibilities include process development and optimization of the technical operations associated with lipid based suspension and oral drug products and process characterization. This position will report to the Vice President, Manufacturing & Supply Chain.
Responsibilities
Ensures all drug process development and manufacturing development activities for drug products are aligned with Matinas BioPharma's project goals and timelines.
Design and execute various studies to support process selection and manufacturing unit operations including stability and excipient selection, freeze/thaw, mixing, filtration, bottle filling and spray drying,
Lead/manage DOE and risk assessments to finalize the DP formulation and manufacturing processes.
Works collaboratively with internal stakeholder functions such as Clinical Manufacturing, Project Management, Clinical, and Regulatory to meet program goals. Coordinates seamlessly with colleagues overseeing formulation and analytical development activities.
Oversee activities related to drug product/clinical supply at external vendors/CMO’s, including oversight of scale up, process optimization & prototyping.
Reviews all drug product related technical documents, including process research & development reports, master batch record documentation, campaign reports, and validation protocols & reports.
Takes an active role and applies subject matter expertise in establishing phase-appropriate process development and manufacturing strategies,
Implements Quality by Design (QbD) and applies risk-based principles to drug product development programs, including technical & quality risk assessments, Design of Experiments, and identification of critical quality attributes, critical process parameters, and manufacturing control strategies.
Supports production deviation & event investigations.
Provide technical support for IND and BLA filings.
Assists in the responses to health authority questions.
Leads process optimization efforts for improving functional processes and technical operations within CMC.
Participates in technical audits during vendor selection.
Qualifications and Experience
BS/MS with at least fifteen (15) years of experience or a Ph.D. with at least ten (10) years of experience in a bio-pharmaceutical area with appropriate therapeutic product development experience.
Experience in the development of lipid based drugs is a plus.
Successful leadership of drug product development.
Excellent awareness & understanding of other stakeholder roles and drug product development's relationship to them.
Excellent working knowledge of CGMP, regulatory guidance, and compendial requirements, including FDA, EMA, ICH, WHO, USP-NF and EP.
Demonstrable experience as a primary author of CMC sections in regulatory filings, such as IND, IMPD, and NDA.
Excellent technical writing, oral, presentation, and interpersonal communication skills.
Excellent data presentation & analysis skills, including the creation of publication quality tables & graphs.
Fluent in the Microsoft ecosystem, including Office & SharePoint, and PDF publication & editing software such as Adobe Acrobat. Comfortable with electronic records & digital workflows.
Detail-oriented and organized.
Possesses high integrity and exceptional work ethic.
Must be flexible and able to multitask, prioritize, meet deadlines in a fast-paced environment, and be adaptable to setbacks. Exceptional problem-solving skills.
Team oriented; ability to work collaboratively with internal colleagues and vendors.
Understands and anticipates the impact of business and commercial needs on advanced-stage drug development.
Some travel required, including both domestic and international (10%).
BACK TO CAREERS
Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG)
Download as PDFSeptember 15, 2020 7:00am EDT
- FDA Agreement to Move Directly into Phase 3 -
- FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG -
BEDMINSTER, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced the result of its End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) concerning the development and registration pathway for MAT9001, a potential best-in-class prescription omega-3 therapy. The official minutes of the meeting confirmed that the FDA and Matinas are aligned on key next steps for MAT9001’s Phase 3 development program and registration pathway for an initial indication to treat severe hypertriglyceridemia (SHTG), a clinical disorder associated with major complications such as pancreatitis and atherosclerotic cardiovascular disease. The Company remains on track to initiate its Phase 3 program in the first half of 2021.
“We are extremely pleased with the outcome of our meeting with FDA and are encouraged by the highly collaborative and strategic input we received for our program. I am very proud of what we have accomplished as a team and look forward to initiating the Phase 3 trial in SHTG and maximize the clinical opportunities for MAT9001,” said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma.
The Company and the FDA agreed on key elements of the Phase 3 program to support a New Drug Application (NDA) filing, including the requirement for a single 12-week study to support efficacy in SHTG. Moreover, FDA provided flexibility to Matinas in the totality of patient safety data needed to meet regulatory requirements for NDA submission. The Company is evaluating several ways to both meet these requirements and to potentially provide additional data differentiating MAT9001 from other prescription omega-3 drugs.
“Alignment with the FDA on our Phase 3 development program provides clarity about our development pathway for MAT9001 in SHTG,” said Jerome D. Jabbour, CEO of Matinas BioPharma. “With this important feedback from FDA, we can confidently move forward with our streamlined 505(b)2 registration for MAT9001. Our level of enthusiasm for this potential best-in-class omega-3 therapy remains high, and we look forward to forthcoming near-term data from our ongoing ENHANCE-IT head to head trial of MAT9001 vs. Vascepa to once again highlight the differentiation between these two products and the potential significant clinical benefits of MAT9001 for patients with hypertriglyceridemia and cardiovascular disease.”
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors.
MAT9001, the Company’s lead product candidate for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia. MAT9001 is currently in a second head-to-head comparative study against Vascepa® (ENHANCE-IT), with topline data expected in the first quarter of 2021.
In addition, Matinas is developing a portfolio of products based upon its proprietary lipid nano-crystal (LNC) drug delivery platform, which can solve complex challenges relating to the safe and effective delivery of potent medicines, making them more targeted, less toxic and orally bioavailable.
MAT2203, the Company’s lead product candidate utilizing its LNC platform, is an oral, encochleated formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis, with potential cohort progression anticipated in the fourth quarter of 2020.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.
Investor and Media Contacts
Peter Vozzo
Westwicke
443-213-0505
peter.vozzo@westwicke.com
Ian Cooney
Director – Investor Relations & Corporate Development
Matinas Biopharma, Inc.
(415) 722-4563
icooney@matinasbiopharma.com
Primary Logo
Source: Matinas BioPharma Holdings, Inc.
Released September 15, 2020
There were 5 job offerings listed early this week,now the are 8...
https://www.matinasbiopharma.com/contact#row-2273
lOOKS like another new job offering at MTNB
https://www.matinasbiopharma.com/contact/job/2276/technician-clinical-manufacturing
The NIH, headed by Fauci, asked MTNB to create a safe, oral version of Remdesivir, which it has been working on for many months.
So, when Fauci now says he wants to treat Covid with an orally administered anti-viral drug that can be given safely for 7-10 days, it sure sounds as if he is referring to the LNC version of Remdesivir.
If this turns out to be the case, MTNB will be worth at least $10 per share.
LM
in a few more days i'll know if this camp out has been worth it.
GLTAL
Will be interesting to see who Matinas may draw over to fill some of these positions.
RISK,REWARD? perhaps the best investments I 've ever made in bio's buying at this level...
Followers
|
61
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
869
|
Created
|
07/21/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |